This review explores the dynamic landscape of hepatocellular carcinoma (HCC) treatment,
emphasizing on recent developments across various stages and therapeutic approaches …

Hepatocellular carcinoma (HCC) represents the most common primary liver cancer and is
considered a major global health problem as one of the leading causes of cancer-related …

Background/Aims Atezolizumab plus bevacizumab (ATE+ BEV) therapy has become the
recommended first-line therapy for patients with unresectable hepatocellular carcinoma …

Although durvalumab plus tremelimumab (Dur/Tre) has been approved as first-line therapy
for patients with unresectable hepatocellular carcinoma (u-HCC), its outcomes in real-world …

Over the past years, there has been a remarkable advance in the systemic treatment options
for advanced HCC. The overall survival has gradually increased over time, with larger …

Purpose The aim of the present study was to assess the efficacy and safety of transarterial
chemoembolization (TACE) combined with atezolizumab and bevacizumab (hereafter …

Liver cancer is the third leading cause of cancer-related deaths worldwide, with
hepatocellular carcinoma (HCC) accounting for approximately 90% of primary liver cancers …

Simple Summary Systemic therapy for hepatocellular carcinoma has been advancing
rapidly. With the advent of drugs with high response rates and combination immunotherapy …

Introduction Advanced hepatocellular carcinoma (HCC) represents a significant global
health burden, whose treatment has been recently revolutionized by the advent of biologic …

The relationship between antitumor response and tumor marker changes was evaluated in
patients with advanced hepatocellular carcinoma treated with durvalumab plus …